Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Jacobs

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Physiological Reports|November 13, 2025
A pilot study on midazolam sedation for murine echocardiography: A potential alternative to isoflurane anesthesia and awake imagingBart Jacobs, Sarah Derde, Lies Langouche, et al.
Frontiers in Immunology|July 12, 2023
Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvantGwenn Waerlop, Yorick Janssens, Bart Jacobs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancerHans Prenen, Jef De Schutter, Bart Jacobs, et al.
JAMA Oncology|February 13, 2016
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal CancerJenny F Seligmann, Faye Elliott, Susan D Richman, et al.
Journal of Translational Medicine|April 21, 2016
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitorsMax Schreuer, Geert Meersseman, Sari Van Den Herrewegen, et al.
FEBS Letters|November 21, 2012
microRNAs in colon cancer: a roadmap for discoverySimona Rossi, Antonio Fabio Di Narzo, Pieter Mestdagh, et al.
The Lancet. Infectious Diseases|July 30, 2023
Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trialIsabel Leroux-Roels, Paul Willems, Gwenn Waerlop, et al.
JAMA Oncology|October 28, 2017
Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal CancerJenny F Seligmann, Ace J Hatch, Susan D Richman, et al.
Vaccines|September 28, 2024
Safety and Immunogenicity of a Carbohydrate Fatty Acid Monosulphate Ester Adjuvant Combined with a Low-Dose Quadrivalent Split-Virion Inactivated Influenza Vaccine: A Randomised, Observer-Blind, Active-Controlled, First-in-Human, Phase 1 StudyValentino D'Onofrio, Sharon Porrez, Bart Jacobs, et al.
Annals of Botany|August 9, 2016
Scalariform-to-simple transition in vessel perforation plates triggered by differences in climate during the evolution of AdoxaceaeFrederic Lens, Rutger A Vos, Guillaume Charrier, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Physiological Reports|November 13, 2025
A pilot study on midazolam sedation for murine echocardiography: A potential alternative to isoflurane anesthesia and awake imagingBart Jacobs, Sarah Derde, Lies Langouche, et al.
Frontiers in Immunology|July 12, 2023
Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvantGwenn Waerlop, Yorick Janssens, Bart Jacobs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancerHans Prenen, Jef De Schutter, Bart Jacobs, et al.
JAMA Oncology|February 13, 2016
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal CancerJenny F Seligmann, Faye Elliott, Susan D Richman, et al.
Journal of Translational Medicine|April 21, 2016
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitorsMax Schreuer, Geert Meersseman, Sari Van Den Herrewegen, et al.
FEBS Letters|November 21, 2012
microRNAs in colon cancer: a roadmap for discoverySimona Rossi, Antonio Fabio Di Narzo, Pieter Mestdagh, et al.
The Lancet. Infectious Diseases|July 30, 2023
Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trialIsabel Leroux-Roels, Paul Willems, Gwenn Waerlop, et al.
JAMA Oncology|October 28, 2017
Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal CancerJenny F Seligmann, Ace J Hatch, Susan D Richman, et al.
Vaccines|September 28, 2024
Safety and Immunogenicity of a Carbohydrate Fatty Acid Monosulphate Ester Adjuvant Combined with a Low-Dose Quadrivalent Split-Virion Inactivated Influenza Vaccine: A Randomised, Observer-Blind, Active-Controlled, First-in-Human, Phase 1 StudyValentino D'Onofrio, Sharon Porrez, Bart Jacobs, et al.
Annals of Botany|August 9, 2016
Scalariform-to-simple transition in vessel perforation plates triggered by differences in climate during the evolution of AdoxaceaeFrederic Lens, Rutger A Vos, Guillaume Charrier, et al.
Pageof 8